Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
102.11
+0.33 (0.32%)
At close: Jan 9, 2026, 4:00 PM EST
102.18
+0.07 (0.07%)
After-hours: Jan 9, 2026, 6:49 PM EST
Exact Sciences Market Cap
Exact Sciences has a market cap or net worth of $19.38 billion as of January 9, 2026. Its market cap has increased by 77.66% in one year.
Market Cap
19.38B
Enterprise Value
20.91B
1-Year Change
77.66%
Ranking
Category
Stock Price
$102.11
Market Cap Chart
Since February 1, 2001, Exact Sciences's market cap has increased from $280.30M to $19.38B, an increase of 6,812.95%. That is a compound annual growth rate of 18.50%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 9, 2026 | 19.35B | 0.54% |
| Dec 31, 2025 | 19.24B | 85.04% |
| Dec 31, 2024 | 10.40B | -22.27% |
| Dec 29, 2023 | 13.38B | 52.09% |
| Dec 30, 2022 | 8.80B | -34.41% |
| Dec 31, 2021 | 13.41B | -32.71% |
| Dec 31, 2020 | 19.93B | 65.99% |
| Dec 31, 2019 | 12.01B | 54.83% |
| Dec 31, 2018 | 7.76B | 23.28% |
| Dec 29, 2017 | 6.29B | 334.31% |
| Dec 30, 2016 | 1.45B | 62.89% |
| Dec 31, 2015 | 889.20M | -61.54% |
| Dec 31, 2014 | 2.31B | 177.43% |
| Dec 31, 2013 | 833.30M | 23.40% |
| Dec 31, 2012 | 675.30M | 57.12% |
| Dec 30, 2011 | 429.80M | 77.46% |
| Dec 31, 2010 | 242.20M | 100.66% |
| Dec 31, 2009 | 120.70M | 678.71% |
| Dec 31, 2008 | 15.50M | -82.22% |
| Dec 31, 2007 | 87.20M | 15.65% |
| Dec 29, 2006 | 75.40M | 29.55% |
| Dec 30, 2005 | 58.20M | -41.97% |
| Dec 31, 2004 | 100.30M | -48.48% |
| Dec 31, 2003 | 194.70M | -5.62% |
| Dec 31, 2002 | 206.30M | 7.06% |
View and export this data all the way back to 2001. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 952.29B |
| Johnson & Johnson | 492.44B |
| AbbVie | 388.97B |
| UnitedHealth Group | 311.59B |
| AstraZeneca | 295.57B |
| Merck & Co. | 274.34B |
| Novartis AG | 272.98B |
| Novo Nordisk | 263.81B |